(a) Sequence alignment of crucial residues in ECL2 from representative aminergic receptors. (b) Display of residues in ECL2s from TAAR1 and other aminergic receptors which will get section in ligand recognition and binding pocket development.In the uk and a few other countries, the name used in drugs legislation is methylamphetamine. Other commonly